Rabies post-exposure treatment and side-effects in man using HDC (MRC 5) vaccine.
126 patients underwent a post-exposure antirabies treatment using the beta-propiolactone inactivated (HDC) MRC-5 vaccine. The immunization schedule consisted of single doses of 1 ml of vaccine administered on days 0, 3, 7, 14, 30 and 90. Within the post-exposure group several patients suffered wounds from known rabid animals. Serum samples were collected on days 0, 14, 30, 90 and 104. Neutralizing antibodies against the rabies virus were determined in the rapid-fluorescent-focus-inhibition (RFFI) test. The rise in neutralizing antibodies was steeper than that in the prophylactic group whereas the mean titer at day 30 did not significantly exceed the values obtained with the preventive immunization scheme. A 1 ml booster injection on day 90 resulted in a three-fold increase of antibody titer within two weeks. Although no major side-effects were observed, an analysis of questionnaires filled out by the patients is presented.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000829:Animals, Domestic; D000835:Animals, Wild; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D046508:Culture Techniques; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008875:Middle Aged; D011818:Rabies / Q000209:etiology / Q000628:therapy*; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D014613:Vaccines, Attenuated
D011819:Rabies Vaccines; D014613:Vaccines, Attenuated